Please login to the form below
heart failure
This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.
Moderna inks R&D agreements with Vertex and Chiesi
PAH is a rare and progressive disorder, which occurs when arteries in the lungs constrict, which forces the heart to work harder, often causing heart failure.
Latest news
-
AZ’s Farxiga cuts risk of death in chronic kidney disease
AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual ... the risk of hospitalisation for heart failure and
-
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial
The EMPEROR-Reduced trial evaluated SGLT2 inhibitor Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF). ... Aside from the EMPEROR-Reduced trial, Boehringer/Lilly is also investigating Jardiance as a treatment
-
AstraZeneca escapes pandemic impact as new drugs bolster revenues
Over in its CVRM franchise, total revenue reached $2.26bn thanks to strong sales of its heart failure med Farxiga (dapagliflozin) and Brilinta (ticagrelor).
-
Novartis stumbles in Q2 as COVID-19 impacts sales
Its psoriasis and arthritis drug Cosentyx (secukinumab) also saw a sales rise of 12% to $944m, while its heart failure drug Entresto (sacubitril/valsartan) climbed 40% to $508m.
-
Merck, Bayer get FDA priority review for heart failure drug
Target action date set for January 2021. Merck and Bayer’s high-risk heart failure drug vericiguat has scored a priority review from the US Food and Drug Administration (FDA), four ... a biomarker in patients with worsening chronic heart failure with
More from news
Approximately 45 fully matching, plus 247 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy
-
20 for 2020 – Five pharma companies to watch
Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it secures approval for heart failure in both diabetic
-
Integrating patient reported outcomes into clinical trials
Drug developers have responded by putting PROs at the heart of their clinical trial designs. ... The performance of Novartis’ heart failure drug Entresto offers one example of that potential.
-
Leading AstraZeneca’s return to growth in Europe
I think it’s about confidently expressing your ability – or perhaps more importantly, just your willingness to do something, versus being afraid of failure. ... This is the first large real-world evidence study of its kind, evaluating the risk of
-
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines. Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to
More from intelligence
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest appointments
-
uniQure appoints chief executive officer
for congestive heart failure and Huntington's disease into the clinic.”.
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
-
Acorda appoints new CFO
pain and heart failure. .
-
Cardioxyl appoints Novartis scientist as chief medical officer
Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at ... Her unique combination of both early- and late-stage
-
CytomX makes senior changes following Pfizer deal
Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he worked in the development of products in nephrology, diabetes and heart failure.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
What is changing in cardiovascular disease care?
Introduction. Cardiovascular disease (CVD), which covers a wide range of conditions, such as coronary heart disease, heart valve disease (HVD) and strokes, is responsible for a quarter of all deaths in ... Integrated care organisations. Many CVD
-
What is changing in mental health and dementia care?
From 2020/21, PCNs will use digital health records and health management tools to identify moderate frailty and detect and intervene to treat undiagnosed disorders, such as heart failure.
-
ECHO Medical Communications
ECHO delivers dedicated medical communications specialising in the areas of endocrinology, cardiovascular disease, heart failure and obesity.
-
ECHO Medical Communications
ECHO delivers dedicated medical communications specialising in the areas of endocrinology, cardiovascular disease, heart failure and obesity.
-
90TEN shortlisted with six entries at the Communiqué Awards across PR and medical education
The campaigns span psoriasis, heart failure and HIV and cover medical education and PR, but they all have one thing in common: the power to change lives. ... Shining a light on heart failure management in the UK (90TEN and Novartis) – Excellence in
More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Roche’s Ocrevus boasts positive long-term data in MS
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
